A systematic literature review published in the European Journal of Internal Medicine this month has concluded there is evidence to support the therapeutic effect of cannabis and cannabinoids.
Conducted by a 16-member committee of the National Academies of Sciences, Engineering and Medicine, the review considered 10,000 recent abstracts focusing on 11 priority health areas.
The report concluded that there was "conclusive or substantial evidence that cannabis or cannabinoids are effective for the treatment of pain in adults; chemotherapy-induced nausea and vomiting and spasticity associated with multiple sclerosis".
Moderate evidence was found for secondary sleep disturbances, but evidence supporting improvement in appetite, Tourette syndrome, anxiety, PTSD, cancer, irritable bowel syndrome, epilepsy and neurodegenerative disorders was described as "limited, insufficient or absent" - visit ejinme.com.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Apr 18
